102976-53-4

Upstream product

• 4394-54-1 1-(3'-chloro-4'-methoxyphenyl)-1-propanone 
• 102151-33-7 3-Chloro-4-methoxybenzonitrile 
• 36590-49-5 3-chloro-4-methoxybenzoyl chloride 
• 89978-93-8 3-chloro-4-methoxy-benzoic acid amide 
• 37908-98-8 methyl 3-chloro-p-anisate 
• 37908-96-6 3-chloro-4-methoxy benzoic acid 

Relevant academic research and scientific papers

Identification and Structural Characterization of Three New Metabolites of Bupropion in Humans

Bupropion is a widely used antidepressant and the recommended CYP2B6 probe drug. However, current understanding of bupropion elimination pathways is limited. Bupropion has three active circulating metabolites, OH-bupropion, threohydrobupropion, and erythrohydrobupropion, but together with bupropion these metabolites and their conjugates in urine represent only 23% of the dose, and the majority of the elimination pathways of bupropion result in uncharacterized metabolites. The aim of this study was to determine the structures of the uncharacterized bupropion metabolites using human clinical samples and in vitro incubations. Three new metabolites, 4′-OH-bupropion, erythro-4′-OH-hydrobupropion, and threo-4′-OH-hydrobupropion, were detected in human liver microsome incubations and were isolated from human urine. The structures of the metabolites were confirmed via comparison of UV absorbance, NMR spectra, and mass spectral data to those of the synthesized standards. In total, these metabolites represented 24% of the drug related material excreted in urine.

Design and synthesis of a hapten for the radioimmunoassay of bupropion

The synthesis of a hapten useful in the radioimmunoassay of bupropion is described. Since bupropion has no functional group that can be easily derivatized, a hydroxypropyl group was incorporated into the molecule. Studies in cross-reactivity with possible metabolites required the synthesis of the 4'-hydroxy analogue of bupropion. This synthesis is also described.